Zydus Lifesciences shares were trading flat on October 18 after the company received final approval to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg from the United States Food and Drug Administration (USFDA).
At 10:01am, Zydus Lifesciences was quoting at Rs 1,020.75, down Rs 0.15, or 0.01 percent, on the BSE.
Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
The tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad.
The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.
Catch all the market action on our live blog
Earlier in this month, the company formalized the Memorandum of Agreement (MoA) with Indian Council of Medical Research (ICMR) to initiate Phase 2 clinical trials of Desidustat in patients with Sickle Cell Disease.
On October 10, the company received tentative approval from the (USFDA to manufacture Enzalutamide Tablets, 40 mg and 80 mg.
On October 2, the company received final approval from the USFDA to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
